All In Biotech

Drug Trial Radar · NCT06830720

A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence

A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence to Evaluate Real-world Effectiveness, Safety Profile, Patient Compliance and Quality of Life

Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

3,250

Planned (sponsor's estimate)

Start

Feb 20, 2025

Primary completion

Jun 30, 2030

Study completion Jun 30, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 17, 2025

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This non-interventional observational study evaluates the real-world effectiveness and safety profile of ribociclib in combination with an aromatase inhibitor for adjuvant treatment in patients with HR+/HER2- early breast cancer at high risk of recurrence, as well as patient compliance and quality of life.

Conditions

  • Breast Neoplasms

Interventions

  • ribociclib + AI ± LHRHDrug

    ribociclib in combination with an aromatase inhibitor ± LHRH as described in the current effective summary of product characteristics. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.

  • abemaciclib + ET ± LHRHDrug

    abemaciclib in combination with an endocrine therapy ± LHRH as described in the current effective summary of product characteristics. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.

  • ET mono ± LHRHDrug

    endocrine monotherapy ± LHRH. This is an observational study. There is no treatment allocation. The decision to initiate treatment will be based solely on clinical judgement.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive disease-free survival (iDFS) for adjuvant therapy with ribociclib + AI ± LHRH in participants with HR+/HER2- eBC at high risk of recurrenceTime frame: 36 months

Locations

287 sites in 2 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Graz, Austria · Recruiting

  • Novartis Investigative Site

    Klagenfurt, Austria · Recruiting

  • Novartis Investigative Site

    Leoben, Austria · Recruiting

  • Novartis Investigative Site

    Schwaz, Austria · Recruiting

  • Novartis Investigative Site

    Steyr, Austria · Recruiting

  • Novartis Investigative Site

    Vienna, Austria · Recruiting

  • Novartis Investigative Site

    Vienna, Austria · Recruiting

  • Novartis Investigative Site

    Vienna, Austria · Recruiting

  • Novartis Investigative Site

    Vienna, Austria · Recruiting

  • Novartis Investigative Site

    Wiener Neustadt, Lower Austria, Austria · Recruiting

  • Novartis Investigative Site

    Innsbruck, Tyrol, Austria · Recruiting

  • Novartis Investigative Site

    Linz, Upper Austria, Austria · Recruiting

  • Novartis Investigative Site

    Aachen, Germany · Recruiting

  • Novartis Investigative Site

    Amberg, Germany · Recruiting

  • Novartis Investigative Site

    Apolda, Germany · Recruiting

  • Novartis Investigative Site

    Arnsberg, Germany · Recruiting

  • Novartis Investigative Site

    Augsburg, Germany · Recruiting

  • Novartis Investigative Site

    Bad Friedrichshall, Germany · Recruiting

  • Novartis Investigative Site

    Bad Kreuznach, Germany · Recruiting

  • Novartis Investigative Site

    Bad Langensalza, Germany · Recruiting

  • Novartis Investigative Site

    Bad Mergentheim, Germany · Recruiting

  • Novartis Investigative Site

    Bad Reichenhall, Germany · Recruiting

  • Novartis Investigative Site

    Bad Saarow, Germany · Recruiting

  • Novartis Investigative Site

    Bad Soden, Germany · Recruiting

  • Novartis Investigative Site

    Balingen, Germany · Recruiting

  • Novartis Investigative Site

    Bautzen, Germany · Recruiting

  • Novartis Investigative Site

    Bayreuth, Germany · Recruiting

  • Novartis Investigative Site

    Berlin, Germany · Recruiting

  • Novartis Investigative Site

    Berlin, Germany · Recruiting

  • Novartis Investigative Site

    Berlin, Germany · Recruiting

  • Novartis Investigative Site

    Berlin, Germany · Recruiting

  • Novartis Investigative Site

    Berlin, Germany · Recruiting

  • Novartis Investigative Site

    Berlin, Germany · Recruiting

  • Novartis Investigative Site

    Biberach, Germany · Recruiting

  • Novartis Investigative Site

    Böblingen, Germany · Recruiting

  • Novartis Investigative Site

    Bochum, Germany · Recruiting

  • Novartis Investigative Site

    Bonn, Germany · Recruiting

  • Novartis Investigative Site

    Bonn, Germany · Recruiting

  • Novartis Investigative Site

    Bonn, Germany · Recruiting

  • Novartis Investigative Site

    Bottrop, Germany · Recruiting

Showing 40 of 287 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.